<p>（第一财经）12 月 9 日——中国已将日本的卫材和美国的礼来公司两种昂贵的阿尔茨海默病治疗药物纳入其首个商业健康保险覆盖的创新药物目录中。完整的治疗费用超过 30 万元人民币（42,434 美元），患者预计可节省高达 85% 的费用。</p>
<p>卫材的来可那单抗和礼来的多那单抗于去年在中国获得批准，已被纳入国家医疗保障局于 12 月 7 日发布的首个商业健康保险创新药物清单中。尽管患者每种药物需要支付的确切比例尚不清楚，但他们可能只需支付成本的 15% 到 50%。</p>
<p>这意味着可观的节省。来自复旦大学华东医院神经内科的余金泰告诉第一财经，来可那单抗的年治疗费用超过 20 万元人民币（28,300 美元），而多那单抗则超过 30 万元人民币。典型的治疗课程通常持续 18 个月，这意味着患者将面临至少 30 万元人民币，甚至接近 50 万元人民币（70,740 美元）的账单。</p>
<p>“将这些药物纳入商业健康保险的创新药物目录，可以帮助早期患者获得更实惠的创新疗法，减缓疾病进展，提高生活质量，” 福建医科大学附属联合医院神经内科的陈晓春表示。</p>
<p>礼来的多那单抗目前是中国唯一批准用于早期阿尔茨海默病治疗的淀粉样蛋白药物，已有证据表明患者在淀粉样斑块清除后可以停止治疗。</p>
<p>据第一财经了解，它已被纳入北京、广州和深圳等 10 个省市的医疗保险覆盖范围。但仅在特大城市被医疗保险覆盖并不足以惠及大多数患者。</p>
<p>“除了国家医疗保险的基本作用外，还应利用商业健康保险作为补充，以确保突破性疗法得到合理评估，” 一位业内人士表示。“这将使阿尔茨海默病的早期患者能够以可负担、及时和公平的方式获得创新药物，并加速这些治疗的实际影响。”</p>
<p>与此同时，中国的制药公司，如信达生物和英科药业，也在开发相关疗法。但据第一财经了解，中国大多数阿尔茨海默病药物候选者仍处于早期临床前阶段，距离全面临床试验还有一段时间。</p>
<p>编辑：金·泰勒</p>

礼来

<p>中国已将 Eisai 的 lecanemab 和礼来的 donanemab 纳入首批商业健康保险覆盖的创新药物名单，为患者提供高达 85% 的治疗费用优惠，治疗费用超过 30 万元人民币。此举旨在使创新疗法更加可及和负担得起，提高早期阿尔茨海默病患者的生活质量</p>

<p>(Yicai) Dec. 9 -- China has included two pricey Alzheimer’s disease treatments from Japan’s Eisai and the US’ Eli Lilly in its first directory of innovative medicines that are covered by commercial health insurance. With a full course of treatment costing more than CNY300,000 (USD42,434), patients are set to save up to 85 percent.</p>
<div class="lb-trans"><p>（第一财经）12 月 9 日——中国已将日本的卫材和美国的礼来公司两种昂贵的阿尔茨海默病治疗药物纳入其首个商业健康保险覆盖的创新药物目录中。完整的治疗费用超过 30 万元人民币（42,434 美元），患者预计可节省高达 85% 的费用。</p>
</div><p>Eisai’s lecanemab and Eli Lilly’s donanemab, which were given the green light in China last year, have been included in the first Commercial Health Insurance Innovative Drug List released by the National Healthcare Security Administration on Dec. 7. Although the exact share that patients will need to pay for each drug is still unclear, they are likely to only need to shell out between 15 percent and 50 percent of the cost.</p>
<div class="lb-trans"><p>卫材的来可那单抗和礼来的多那单抗于去年在中国获得批准，已被纳入国家医疗保障局于 12 月 7 日发布的首个商业健康保险创新药物清单中。尽管患者每种药物需要支付的确切比例尚不清楚，但他们可能只需支付成本的 15% 到 50%。</p>
</div><p>This amounts to a substantial saving. Lecanemab costs more than CNY200,000 (USD28,300) for a year of treatment while donanemab exceeds CNY300,000, Yu Jintai from the department of neurology at Fudan University's Huashan Hospital told Yicai. A typical course of treatment usually lasts 18 months, meaning that patients will face bills of at least CNY300,000 and up to almost CNY500,000 (USD70,740).</p>
<div class="lb-trans"><p>这意味着可观的节省。来自复旦大学华东医院神经内科的余金泰告诉第一财经，来可那单抗的年治疗费用超过 20 万元人民币（28,300 美元），而多那单抗则超过 30 万元人民币。典型的治疗课程通常持续 18 个月，这意味着患者将面临至少 30 万元人民币，甚至接近 50 万元人民币（70,740 美元）的账单。</p>
</div><p>“By including these drugs in the directory of innovative drugs for commercial health insurance, it can help early-stage patients access innovative therapies that are more affordable, slow disease progression and improve quality of life,” said Chen Xiaochun from the department of neurology at Fujian Medical University’s Union Hospital.</p>
<div class="lb-trans"><p>“将这些药物纳入商业健康保险的创新药物目录，可以帮助早期患者获得更实惠的创新疗法，减缓疾病进展，提高生活质量，” 福建医科大学附属联合医院神经内科的陈晓春表示。</p>
</div><p>Eli Lilly’s donanemab is currently the only approved amyloid protein drug in China for the treatment of early Alzheimer’s disease where there is evidence showing that patients can stop treatment after the amyloid plaques are cleared.</p>
<div class="lb-trans"><p>礼来的多那单抗目前是中国唯一批准用于早期阿尔茨海默病治疗的淀粉样蛋白药物，已有证据表明患者在淀粉样斑块清除后可以停止治疗。</p>
</div><p>It was included in the medical insurance coverage of 10 provinces and municipalities such as Beijing, Guangzhou and Shenzhen as of this year, Yicai learned. But only being covered by medical insurance in the megacities is not enough to benefit most patients.</p>
<div class="lb-trans"><p>据第一财经了解，它已被纳入北京、广州和深圳等 10 个省市的医疗保险覆盖范围。但仅在特大城市被医疗保险覆盖并不足以惠及大多数患者。</p>
</div><p>“Apart from the national medical insurance’s basic role, it should also leverage commercial health insurance as a supplement to ensure that breakthrough therapies are properly valued,” an industry insider said. “This will allow early-stage patients of Alzheimer’s disease to gain access to innovative drugs in an affordable, timely and fair way, and speed up the real-world impact of these treatments.”</p>
<div class="lb-trans"><p>“除了国家医疗保险的基本作用外，还应利用商业健康保险作为补充，以确保突破性疗法得到合理评估，” 一位业内人士表示。“这将使阿尔茨海默病的早期患者能够以可负担、及时和公平的方式获得创新药物，并加速这些治疗的实际影响。”</p>
</div><p>Meanwhile, Chinese drugmakers, such as Simcere and Innocare Pharma, are also developing related therapies. But most drug candidates for Alzheimer’s disease in China are still in the early preclinical stage and it will take some time before they reach full clinical trials, Yicai learned.</p>
<div class="lb-trans"><p>与此同时，中国的制药公司，如信达生物和英科药业，也在开发相关疗法。但据第一财经了解，中国大多数阿尔茨海默病药物候选者仍处于早期临床前阶段，距离全面临床试验还有一段时间。</p>
</div><p>Editor: Kim Taylor</p>
<div class="lb-trans"><p>编辑：金·泰勒</p>
</div>

中国将昂贵的阿尔茨海默症药物纳入商业保险的首批新药名单